2026-07-10 FDA Warning Letter: Alembic Pharmaceuticals Ltd. Cited for In Vivo Bioavailability-Bioequivalence Studies – Clinical
Letter issued · posted to fda.gov .
Subject as published: In Vivo Bioavailability-Bioequivalence Studies – Clinical
TL;DR
The short version: FDA's Center for Drug Evaluation and Research issued a warning letter (26-HFD-45-07-01) to Alembic Pharmaceuticals Ltd. on July 10, 2026, following an inspection of its Vadodara bioequivalence facility (March 3-7, 2025) regarding conduct of an in vivo bioequivalence clinical study. The FDA determined Alembic failed to obtain legally effective informed consent under 21 CFR 50.20 and 21 CFR 312.60 because the informed consent form stated "no part of it is of an experimental nature," creating inconsistencies that may have misled subjects about the experimental nature of the study and unduly influenced their participation decisions. Alembic's response acknowledged bioequivalence studies are experiments and implemented corrective actions including revised SOPs, updated ICF templates, personnel training, and protocol amendments with Ethics Committee approval.
Argus analysis
# FDA Warning Letter Analysis: Alembic Pharmaceuticals Ltd.
**Company and Findings**
Alembic Pharmaceuticals Ltd., operating the Alembic Research Centre in Vadodara, Gujarat, India, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on July 10, 2026. The FDA inspected the facility between March 3–7, 2025, as part of its Bioresearch Monitoring Program, which evaluates the conduct of clinical research and protection of human subjects. The inspection focused on an in vivo bioequivalence study of an investigational drug. The FDA determined that the company failed to comply with federal requirements governing clinical investigations and human subject protections.
**Regulatory Citations and Implications**
The primary violations cited are 21 CFR Part 50 (Protection of Human Subjects) and 21 CFR Part 312 (Investigational New Drug Application), specifically 21 CFR 50.20 regarding informed consent. The FDA found that Alembic's informed consent form contained the statement "no part of it is of an experimental nature," which contradicts the regulatory definition of a clinical investigation as an experiment. This language created internal inconsistencies that could mislead study participants about the experimental nature of bioequivalence studies, potentially undermining their ability to make informed decisions and exposing them to undue influence. These violations jeopardize subject rights, safety, and welfare.
**Response Timeline and Industry Watch Points**
Alembic submitted a response to FDA's Form 483 on March 26, 2025, acknowledging the violation and implementing corrective actions, including revised standard operating procedures and updated informed consent templates. However, the FDA deemed the response inadequate because Dr. Doshi had not received training on FDA regulations and revised informed consent forms with ethics committee approval were not provided. The company has 15 business days to submit a substantive written response addressing deficiencies. Peer compliance officers should monitor whether Alembic provides comprehensive documentation of regulatory training, revised study protocols, and evidence of ethics committee approvals before the FDA considers enforcement escalation.
Severity context
Low severity. Procedural or narrow scope; most peer companies resolve in the 15-business-day response window without structural change.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Alembic Pharmaceuticals Ltd. MARCS-CMS 731020 — July 10, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UNITED PARCEL SERVICE AND VIA E-MAIL Reference #: 26-HFD-45-07-01 Product: Drugs Recipient: Recipient Name Pratik Doshi, M.D. Alembic Pharmaceuticals Ltd. Alembic Research Centre Bioequivalence Facility, Alembic Road Next to Bhailal Amin General Hospital Gorwa Vadodara 390003 Gujarat India Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER FDA Ref. No.: 26-HFD-45-07-01 Dear Dr. Doshi: This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at Alembic Research Centre in Vadodara, Gujarat, India, between March 3 and 7, 2025. The investigator representing FDA reviewed your conduct of a clinical in vivo bioequivalence study (Protocol (b)(4) , “ (b)(4) ”) of the investigational drug (b)(4) , performed for (b)(4) . This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected. At the conclusion of the inspection, the FDA investigator presented and discussed with you Form FDA 483, Inspectional Observations. We acknowledge receipt of your March 26, 2025, written response to the Form FDA 483. From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated March 26, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, parts 312 (21 CFR 312) and 50 (21 CFR 50) governing the conduct of clinical investigations and the protection of human subjects. 1 We wish to emphasize the following: You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20]. As a clinical investigator, you are required to obtain informed consent in accordance with 21 CFR part 50. FDA’s regulations at 21 CFR 50.20 state that, except as provided in 21 CFR 50.22, 50.23, and 50.24, 2 no investigator may involve a human being as a subject in research covered by the regulations unless the investigator has obtained the legally effective informed consent of the subject or the subject’s legally authorized representative. Under 21 CFR 50.20, “an investigator shall seek … [informed] consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence.” You failed to seek informed consent for the above-referenced clinical investigation under circumstances that provided the prospecti…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Alembic Pharmaceuticals Ltd.?
- FDA issued the letter (MARCS-CMS 731020) on 2026-07-10 and posted it publicly on fda.gov on 2026-07-21.
- Is the FDA warning letter to Alembic Pharmaceuticals Ltd. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/alembic-pharmaceuticals-ltd-731020-07102026.
- What does a "low" severity rating mean for this letter?
- Low severity. Procedural or narrow scope; most peer companies resolve in the 15-business-day response window without structural change.
- What is the regulatory background for a Warning Letter warning letter?
- FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-07-10 FDA Warning Letter: Alembic Pharmaceuticals Ltd. Cited for In Vivo Bioavailability-Bioequivalence Studies – Clinical. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-alembic-pharmaceuticals-ltd-2026-07-10-warning-letter
"2026-07-10 FDA Warning Letter: Alembic Pharmaceuticals Ltd. Cited for In Vivo Bioavailability-Bioequivalence Studies – Clinical." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-alembic-pharmaceuticals-ltd-2026-07-10-warning-letter.
Argus HQ Research. "2026-07-10 FDA Warning Letter: Alembic Pharmaceuticals Ltd. Cited for In Vivo Bioavailability-Bioequivalence Studies – Clinical." Digital Empire Holdings LLC. Accessed July 22, 2026. https://argushq.ai/fda/warning-letter/fda-wl-alembic-pharmaceuticals-ltd-2026-07-10-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_alembic_pharmaceuticals_ltd_2026_07_10_warning_letter_2026,
title = {2026-07-10 FDA Warning Letter: Alembic Pharmaceuticals Ltd. Cited for In Vivo Bioavailability-Bioequivalence Studies – Clinical},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-alembic-pharmaceuticals-ltd-2026-07-10-warning-letter},
note = {Accessed: July 22, 2026}
}